Evolus (FRA:EVL) Total Liabilities : €216.8 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Evolus Total Liabilities?

Evolus's Total Liabilities for the quarter that ended in Dec. 2024 was €216.8 Mil.

Evolus's quarterly Total Liabilities increased from Jun. 2024 (€199.23 Mil) to Sep. 2024 (€201.57 Mil) and increased from Sep. 2024 (€201.57 Mil) to Dec. 2024 (€216.83 Mil).

Evolus's annual Total Liabilities increased from Dec. 2022 (€150.55 Mil) to Dec. 2023 (€192.28 Mil) and increased from Dec. 2023 (€192.28 Mil) to Dec. 2024 (€216.83 Mil).

Evolus Total Liabilities Historical Data

The historical data trend for Evolus's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolus Total Liabilities Chart

Evolus Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

231.83

155.41

150.55

192.28

216.83

Evolus Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															192.28	191.11	199.23	201.57	216.83

Evolus Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Evolus's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	60.127	+	(116.038	+	38.491
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0.006	+	0	+	2.168)
	=	216.8

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	222.103	-	5.274
	=	216.8

Evolus's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	60.127	+	(116.038	+	38.491
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0.006	+	0	+	2.168)
	=	216.8

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	222.103	-	5.274
	=	216.8

Evolus Total Liabilities Related Terms

Thank you for viewing the detailed overview of Evolus's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Evolus Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evolus Inc (FRA:EVL) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

EOLS:USA 0K16:UK

Address

520 Newport Center Drive, Suite 1200, Newport Beach, CA, USA, 92660

Website

https://www.evolus.com

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Evolus Headlines

No Headlines